2126.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 11:08):

Stats
Dzisiejszy wolumen	844 000
Średni wolumen	299 391
Kapitalizacja rynkowa	683.95M
EPS	HKD0 ( 2024-04-24 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-0.840
ATR14	HKD0.0100 (0.58%)

Wolumen Korelacja

Długi: -0.15 (neutral)

Krótki: -0.50 (neutral)

Signal:(46.733) Neutral

JW THERAP-B Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

JW THERAP-B Korelacja - Waluta/Towar

0.48
( neutral )

0.53
( weak )

0.00
( neutral )

-0.51
( weak negative )

-0.52
( weak negative )

JW THERAP-B Finanse

Annual	2023
Przychody:	HKD173.86M
Zysk brutto:	HKD88.22M (50.74 %)
EPS:	HKD-1.870

FY	2023
Przychody:	HKD173.86M
Zysk brutto:	HKD88.22M (50.74 %)
EPS:	HKD-1.870

FY	2022
Przychody:	HKD145.70M
Zysk brutto:	HKD58.76M (40.33 %)
EPS:	HKD-2.06

FY	2021
Przychody:	HKD30.80M
Zysk brutto:	HKD9.05M (29.37 %)
EPS:	HKD-5.32

Financial Reports:

No articles found.

JW THERAP-B

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.